Rigel Pharmaceuticals published final results from the Phase 1/2 ARROW study of pralsetinib (Gavreto) for RET fusion-positive metastatic NSCLC in the Journal of Clinical Oncology, adding 42 months of follow-up. The updated dataset reports an overall response rate of 70% among patients with measurable disease, with no new safety signals in the longer follow-up period.